Crinetics Pharmaceuticals (CRNX) Current Leases (2021 - 2026)

Crinetics Pharmaceuticals' Current Leases history runs 6 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• In Q1 2026, Current Leases fell 5.04% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (down 5.04% YoY), while the FY2025 annual figure was $6.5 million, down 9.27% from the prior year.
• Current Leases for Q1 2026 stood at $6.5 million, up from $6.5 million in the prior quarter.
• The five-year high for Current Leases was $7.4 million in Q2 2024, with the low at $1.0 million in Q3 2022.
• The 5-year median for Current Leases is $6.4 million (2025), against an average of $4.9 million.
• The sharpest annual moves came in 2024 and 2025: Current Leases jumped 571.33% in 2024, then retreated 13.11% in 2025.
• Crinetics Pharmaceuticals' Current Leases stood at $1.1 million in 2022, then jumped by 297.05% to $4.2 million in 2023, then soared by 71.39% to $7.2 million in 2024, then decreased by 9.27% to $6.5 million in 2025, then climbed by 0.72% to $6.5 million in 2026.
• Business Quant data shows CRNX's Current Leases at $6.5 million in Q1 2026, $6.5 million in Q4 2025, and $6.4 million in Q3 2025.